ArticleMedicine2015
125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy.
Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis.Journal of cardiothoracic surgery · 2022Pooled it
- Study of self-expandable metallic stent placement intraluminalSurgical endoscopy · 2017Trial
- Article
- Percutaneous transhepatic cholangial drainage combined with intra-tumoral iodine-125 seeds implantation and chemotherapy for locally progressive pancreatic head cancer with obstructive jaundice.Journal of contemporary brachytherapy · 2022Article
- CT-guided 125I brachytherapy combined with chemotherapy for the treatment of unresectable or locally advanced pancreatic carcinoma.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Article
- Aortoesophageal fistula involving the central aortic arch salvaged with emergent percutaneous TEVAR, great vessel coverage and in vivo graft fenestration.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Article
- MR-guided 125I seed implantation treatment for maxillofacial malignant tumor.Journal of applied clinical medical physics · 2021Article
- Feasibility and Clinical Value of CT-GuidedFrontiers in oncology · 2021Article
- Article
- A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy.Frontiers in oncology · 2021Article
- The Clinical Value of Computed Tomography (CT)-GuidedCancer management and research · 2021Article
- Clinical efficacy and prognostic factors of CT-guidedCancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Success ofOncoTargets and therapy · 2020Article
- Safety and efficacy ofJournal of cancer research and clinical oncology · 2019Article
- Hybrid optimization based on non-coplanar needles for brachytherapy dose planning.Journal of contemporary brachytherapy · 2019Article
- The efficacy ofInternational journal of clinical and experimental pathology · 2019Article
- DTI and pathological changes in a rabbit model of radiation injury to the spinal cord afterNeural regeneration research · 2018Article
- The application of a three-dimensional visualized seed planning and navigation system inOncoTargets and therapy · 2018Article
- Article
- Dosimetric characterization of GMS BT-125-1Journal of applied clinical medical physics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the safety and effectiveness of computed tomography (CT)-guided I seed implantation for locally advanced nonsmall cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT).We reviewed 78 locally advanced NSCLC patients who had each one cycle of first-line CCRT but had progressive disease identified from January 2006 to February 2015 at our institution. A total of 37 patients with 44 lesions received CT-guided percutaneous I seed implantation and second-line chemotherapy (group A), while 41 with 41 lesions received second-line chemotherapy (group B).Patients in group A and B received a total of 37 and 41 first cycle of CCRT treatment. The median follow-up was 19 (range 3-36) months. After the second treatment, the total response rate (RR) in tumor response accounted for 63.6% in group A, which was significantly higher than that of group B (41.5%) (P = 0.033). The median progression-free survival time (PFST) was 8.00 ± 1.09 months and 5.00 ± 0.64 months in groups A and B (P = 0.011). The 1-, 2-, and 3-year overall survival (OS) rates for group A were 56.8%, 16.2%, and 2.7%, respectively. For group B, OS rates were 36.6%, 9.8%, and 2.4%, respectively. The median OS time was 14.00 ± 1.82 months and 10.00 ± 1.37 months for groups A and B, respectively (P = 0.059). Similar toxicity reactions were found in both groups. Tumor-related clinical symptoms were significantly reduced and the patients' quality of life was obviously improved.CT-guided I seed implantation proved to be potentially beneficial in treating localized advanced NSCLC; it achieved good local control rates and relieved clinical symptoms without increasing side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.